BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20130101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20201008T191500
DTEND;TZID=Africa/Nairobi:20201008T203000
DTSTAMP:20260425T013611
CREATED:20210812T095227Z
LAST-MODIFIED:20211024T153727Z
UID:5878-1602184500-1602189000@kesho-kenya.org
SUMMARY:The Role of Immunotherapy in Cancer Management
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Miriam Mutebi \nSponsor: Beacon \nPresenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi.\n\nImmunotherapy is a type of cancer treatment that boosts the body’s natural defenses to fight cancer cells. It uses substances made by the body or in a laboratory to improve how your immune system works to find and destroy cancer cells. Traditional therapies such as surgery\, radiation\, and cytotoxic/targeted therapy target tumor cells\, while immunotherapy harnesses the body’s immune system to fight diseases. Anti-tumor immunotherapy includes cancer vaccines that educate T cells to better recognize and kill the pre-existing tumor. Adoptive immunotherapy activates and increases T cell numbers to better kill tumor cells. Immunomodulation uses drugs or antibodies to either increase stimulation or to overcome immune inhibition. Many tumors escape the immune response by creating an immunosuppressive microenvironment that prevents an effective anti-tumor response\, mainly through the involvement of the immune checkpoints located in the central or peripheral regions. The immune checkpoints PD-L1 binds to PD-1 and inhibits T cell killing of tumor cell\, therefore\, blocking PD-L1 or PD-1 allows T cell killing of tumor cells\, while CTLA4 regulate the early phase of activation of naïve and memory T cells in response to T cell receptor (TCR) stimulation by peptides presented by MHC ligands expressed by antigen-presenting and processing cells. Its upregulation prevents normal T cell activation. Several checkpoint inhibitors with FDA approval are in clinical use and have proven to be highly effective in the treatment of relapsed\, progressive solid cancers\, with relatively mild but distinct safety profiles. Some immune checkpoint inhibitors available in Kenya\, are quite costly\, and hence National Hospital Insurance Fund (NHIF) is too little to cover for this treatment. Aga Khan is building capacity for PD-L1 analysis\, an immunohistochemistry test\, in addition to next-generation sequencing. More data is required on the safety of immunotherapy and its use on immunocompromised individuals e.g. HIV\, and those with autoimmune diseases\, Since several clinical trials\, are in progress; more new indications are likely to emerge.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/the-role-of-immunotherapy-in-cancer-management/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210812_124901.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200929T190000
DTEND;TZID=Africa/Nairobi:20200929T203000
DTSTAMP:20260425T013611
CREATED:20210604T163946Z
LAST-MODIFIED:20211024T154727Z
UID:5302-1601406000-1601411400@kesho-kenya.org
SUMMARY:Management of Hormone Receptor Positive Breast Cancer
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-hormone-receptor-positive-breast-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193725.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200915T191500
DTEND;TZID=Africa/Nairobi:20200915T203000
DTSTAMP:20260425T013611
CREATED:20210817T111009Z
LAST-MODIFIED:20211024T154755Z
UID:5918-1600197300-1600201800@kesho-kenya.org
SUMMARY:Management of Neuroendocrine Tumors
DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Moderator: Dr. Sitna Mwanzi \nSponsor: Novartis \nPresenters: \n\nNjoki Njiraini\, a consultant clinical oncologist based at the Cancer Centre in Kenyatta University Teaching Research and Referral Hospital.\n\nNeuroendocrine Neoplasms arise from diffuse neuroendocrine cells in the body and are broadly divided into well-differentiated neuroendocrine tumors (NETs)\, including the sporadic small intestine\, pancreatic\, thorax\, and thymus NETs\, and poorly differentiated neuroendocrine carcinomas (NECs)\, classified based on differentiation\, Ki67 levels\, and mitotic figures. NETs arise from neuroendocrine cells throughout the body. There has been increasing incidence over the last 15 years\, with a male preponderance and a more adverse outcome. Diagnosis is mainly through histology and immunohistochemistry. Staging for NECs is mainly by adenocarcinoma staging system\, which mainly involves imaging through CT scan\, MRI\, Contrast-Enhanced USS\, endoscopic USS\, and functional imaging. Treatment is dependent on TNM staging and grading of the disease and includes surgery\, somatostatin analogs\, hepatic-directed therapies\, and chemotherapeutics. For a patient with carcinoid syndrome\, the short-acting octreotide can be considered first\, while waiting for long-acting octreotide to act. Locally\, therapies are available in 20 mg from Novartis retailing at 68000 Kenya shillings\, but 30mg are also available in the market through other distributors. The toxicity profiles should be put into consideration e.g. diarrhea\, although sometimes it’s difficult to differentiate drugs’ side effects from the initial tumor signs. Neuroendocrine carcinomas are classified as small or large cells and mostly the patients have poor outcomes. There is a need to improve imaging and multidisciplinary teams to share local experiences of neuroendocrine patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n\n\n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-neuroendocrine-tumors-2/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_171140.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200908T191500
DTEND;TZID=Africa/Nairobi:20200908T203000
DTSTAMP:20260425T013611
CREATED:20210817T105953Z
LAST-MODIFIED:20211024T154816Z
UID:5914-1599592500-1599597000@kesho-kenya.org
SUMMARY:Management of Iron Overload
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Paresh Dave \nSponsor: Novartis \nPresenters: \n\nPeter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nIron overload is a poly etiologic condition characterized by a moderate to severe increase in the body iron that has or will have negative effects secondary to iron deposition in tissues or body organs. It may be hereditary or acquired. It is important to detect the disease before organ damage occurs. Iron overload affects overall survival partly due to the underlying biology of the disease but also because of the sequelae of iron overload\, including cardiomyopathy\, cardiac events\, liver disease\, and the development of diabetes. For patients with higher serum ferritin levels\, the 100-day post-transplant mortality is worse with inferior overall survival (OS) and a higher rate of graft vs host disease.  Therefore\, iron chelation therapy can improve OS and is effective at reducing serum ferritin levels\, cardiac events\, and diabetes in patients with blood-transfusion-related iron overload. Compliance is highly encouraged to realize successful treatment. The safety profile of each chelator should be evaluated before the initiation of treatment. Patients receiving chemotherapy and who have a drop in blood count parameters require evaluation to find out the causes. Iron studies are required to generate more data. Iron supplementary can be toxic. Patients with severe organ dysfunction can have a combination of iron chelation therapy.  Ferritin levels should be done every 3 months.  Iron chelation OS is not contraindicated in HIV patients with evidence of iron overload.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-iron-overload/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170945.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200827T070000
DTEND;TZID=Africa/Nairobi:20200827T203000
DTSTAMP:20260425T013611
CREATED:20210604T162505Z
LAST-MODIFIED:20211024T154948Z
UID:5294-1598511600-1598560200@kesho-kenya.org
SUMMARY:Cancer and Thrombosis Current Perspective
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Webinar Recording                 \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-and-thrombosis-current-perspective/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193129.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200811T191500
DTEND;TZID=Africa/Nairobi:20200811T201500
DTSTAMP:20260425T013611
CREATED:20210813T143324Z
LAST-MODIFIED:20250622T142511Z
UID:5898-1597173300-1597176900@kesho-kenya.org
SUMMARY:Emerging Therapies in Hodgkin's Lymphoma Management - Treatment Beyond The Basics
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Miriam Mutebi \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nDr. Anna Sureda\, Head of the Clinical Hematology Department and the Stem Cell Transplantation program of Institut Catala d’Oncologia – Hospitalet\, Barcelona\n\nHodgkin’s lymphoma (HL) is one of the most curable hematological malignancies with first-line treatment\, which is a combination of radiotherapy and chemotherapy. Autologous hematopoietic stem cell transplantation (auto-HCT) is the standard therapy for HL patients relapsing after first-line chemotherapy. The use of allogeneic stem cell transplantation (ASCT) has improved the overall survival (OS) of patients over time.  To improve the landscape of chemotherapy treatment for refractory disease\, a new drug\, Brentuximab vedotin\, has been introduced. This drug is an antibody-drug conjugate (ADC) consisting of 3 components; it binds to CD30 forming a complex that is internalized and traffics to the lysosome. The drug was granted accelerated approval by the US FDA in 2011.  The European Medicines Agency (EMA) approved this drug in 2012 for the treatment of adult patients with relapsed or refractory CD30+ HL\, anaplastic large cell lymphoma\, and those at increased risk of relapse or progression following ASCT. The efficacy reported as median observation time from the first dose at study closure was 35.1 months (1.8-72.9). Studies revealed that Brentuximab vedotin and ESHAP are highly effective as second-line therapy for Hodgkin’s patients. Brentuximab vedotin was the first targeted therapy that was tested in patients with relapsed/refractory HL. It was very effective as a single drug in patients that relapse or progress after auto-HCT. Brentuximab vedotin is able to potentially increase the number of patients that are candidates to auto-HCT. It improves progression-free survival (PFS) in those patients with a high risk of relapse after auto-HCT when used as a consolidation strategy. It has demonstrated an adequate and safe toxicity profile\, even in HIV-positive patients with HL. Brentuximab vedotin is being used in other settings with very interesting results (RR setting in combination with chemotherapy\, first line). However\, the cost of the treatment in Kenya is quite high; a single vial costs Kshs. 330\,000. A patient assistance program in partnership with Takeda is helping patients in Kenya who cannot afford to pay\, to complete their treatment. Although this program is run in private hospitals\, physicians seeing patients at public facilities can refer the patients to the private facilities for assistance\, but continue to follow up on the patients. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/emerging-therapies-in-hodgkins-lymphoma-management-treatment-beyond-the-basics/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170809.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200730T191500
DTEND;TZID=Africa/Nairobi:20200730T203000
DTSTAMP:20260425T013611
CREATED:20210810T101728Z
LAST-MODIFIED:20250622T142511Z
UID:5839-1596136500-1596141000@kesho-kenya.org
SUMMARY:Ovarian Cancer\, The Good\, The Bad\, And The Ugly
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi \nSponsor: Merck \nPresenters: \n\nDr. Benjamin Odongo Elly\, Gynecologic Oncologist at Moi Teaching and Referral University.\n\nMoi Teaching and Referral Hospital (MTRH) cancer center offers a holistic approach to cancer treatment. Germ cell tumors account for 10-115% of all ovarian tumors and affect young females of reproductive age. They are very chemosensitive hence are curable\, using fertility-sparing surgery. Stromal tumors account for 3-5% of all ovarian tumors and affect women of all ages. These tumors are diagnosed early and are histologically low-grade\, with a good prognosis\, when treated with surgery\,  followed by adjuvant treatment. However\, some tumors are aggressive and lethal. Epithelial tumors represent 80-85% of all ovarian tumors. They have a poor prognosis and are always detected late. Warning signs include abdominal bloating\, abdominal/pelvic pain\, bowel/bladder symptoms\, and irregular vaginal bleeding. Prevention of ovarian cancer is by avoidance of risk factors and prophylactic surgery in high-risk women. There is currently no good screening test for the general population. Diagnosis is by appropriate physical examination\, pelvic/transvaginal ultrasound\, tumor markers\, and CT scan. The majority of patients are diagnosed with advanced-stage disease (stage III or IV) leading to poor overall 5-year survival. However\, patients are living longer with the disease due to advances in surgery and chemotherapy treatment. As a country\, there is a need to improve the early diagnosis of ovarian cancer through advocacy\, patient education\, human resource\, training capacity building\, and availing resources to the health care facilities.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ovarian-cancer-the-good-the-bad-and-the-ugly/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20191121T200000
DTEND;TZID=Africa/Nairobi:20191121T220000
DTSTAMP:20260425T013611
CREATED:20210420T152935Z
LAST-MODIFIED:20250622T142511Z
UID:4731-1574366400-1574373600@kesho-kenya.org
SUMMARY:TOPIC: Management of Brain Tumors
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nFinally\, KESHO partnered with the Neurological Society of Kenya to discuss the management of brain tumors with a stimulating surgical perspective from Dr Edwin Mogere Neurosurgeon and an in-depth discussion of management of medical symptoms from brain tumors by Dr Judy Kwasa Neurologist. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-management-of-brain-tumors/
LOCATION:Crowne Plaza Hotel
CATEGORIES:CME 2019,Webinar Recording Available
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190829T200000
DTEND;TZID=Africa/Nairobi:20190829T220000
DTSTAMP:20260425T013611
CREATED:20210420T153545Z
LAST-MODIFIED:20250622T142511Z
UID:4736-1567108800-1567116000@kesho-kenya.org
SUMMARY:TOPIC: BCR-ABL and OSTEOGENIC SARCOMA
DESCRIPTION:[vc_row][vc_column][vc_column_text]We took a well-deserved break in July 2019 and came back in August for a mixed presentation on CML and osteogenic sarcoma from Prof Nicholas Abinya Medical Oncologist and Dr Mohammed Ezzi Medical Oncologist. The outcome for patients with CML has significantly improved with TKI therapies\, yet challenges persist in adequate monitoring which is expensive. The lack of co-ordinated multidisciplinary care needed for osteogenic sarcoma led to many lost to follow up and incomplete treatments with poor outcomes. MDTs prior to treatment is a potential strategy for reversing this trend.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-bcr-abl-and-osteogenic-sarcoma/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190829T170000
DTEND;TZID=Africa/Nairobi:20190829T200000
DTSTAMP:20260425T013611
CREATED:20210420T153328Z
LAST-MODIFIED:20250622T142510Z
UID:4734-1567098000-1567108800@kesho-kenya.org
SUMMARY:SSA Breast Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Another busy month for us with three meetings in October. First off\, Prof Asim Jamal Medical Oncologist gave an excellent overview of presentation\, diagnosis and management of neuroendocrine tumors which are not as rare as originally felt. KESHO then partnered with Pathologists Lancet Kenya to discuss molecular diagnostics in hemato-oncology. Speakers from France and our very own experts deliberated on the changing landscape of hemato-oncology and what is practical in our setting. Finally\, a multidisciplinary webinar session on breast cancer concluded our sessions for the month in recognition of the Breast Cancer Awareness month\, with presentations from Dr. Gladwell Kiarie Medical Oncologist\, Dr. Fred Okuku Medical Oncologist\, Dr. Aba Anoa Scott Radiation/Clinical Oncologist and Prof. Ronald Wasike Breast Surgeon.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ssa-breast-cancer/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190627T110000
DTEND;TZID=Africa/Nairobi:20190627T200000
DTSTAMP:20260425T013611
CREATED:20210420T154157Z
LAST-MODIFIED:20250622T142511Z
UID:4738-1561633200-1561665600@kesho-kenya.org
SUMMARY:TOPIC: Paediatric Malignancies; Optimising Care In Acute Leukaemia
DESCRIPTION:[vc_row][vc_column][vc_column_text]We directed our focus on hematology and this time we concentrated on pediatric malignancies. Dr. Jamila Rajab Consultant Haematologist\, Dr. Grace Mbatia Paediatric Oncologist and Dr Festus Njuguna Paediatric Oncologist. We got a glimpse on the myriad challenges our colleagues in hematology face in the management of pediatric hematological malignancies including complicated regimens\, high rate of drop outs and poor supportive care. The outcome was to continue in the process of development of national treatment protocols that can be used which can also help in comparing treatment outcomes in the different settings.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-paediatric-malignancies-optimising-care-in-acute-leukaemia/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190523T200000
DTEND;TZID=Africa/Nairobi:20190523T220000
DTSTAMP:20260425T013611
CREATED:20210420T154450Z
LAST-MODIFIED:20250622T142511Z
UID:4740-1558641600-1558648800@kesho-kenya.org
SUMMARY:TOPIC: Colon Cancer; A Multidisciplinary Approach
DESCRIPTION:[vc_row][vc_column][vc_column_text]This was a busy month for our members with three educational events! Dr. Joe Ruturi Cardiothoracic Surgeon and Dr. Solomon Mutua Clinical Oncologist started off the month with discussions on upper GI cancers\, in particular esophageal cancer. KESHO collaborated with ROCHE in their sub-Saharan MPANGO two-day meeting in which many of our members were speakers. The conference focused on triple negative and HER2 breast cancer\, colon and lung cancer. The month ended with an excellent multidisciplinary meeting on colon cancer spearheaded by our very own past Chair\, Dr. Gladwell Kiarie Medical Oncologist and Dr. Rajendra Chauhan Surgical Oncologist. There was a lot of input from our surgical and radiation colleagues.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-colon-cancer-a-multidisciplinary-approach/
LOCATION:Radisson Blu\, Upperhill Nairobi\, Nairobi\, Nairobi\, 00100\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190427T200000
DTEND;TZID=Africa/Nairobi:20190427T220000
DTSTAMP:20260425T013611
CREATED:20210420T155152Z
LAST-MODIFIED:20250622T142511Z
UID:4743-1556395200-1556402400@kesho-kenya.org
SUMMARY:TOPIC: HIV Malignancies Symposium
DESCRIPTION:[vc_row][vc_column][vc_column_text]KESHO held a half-day joint symposium with the HIV Clinicians Society discussing the various aspects of HIV related malignancies and how we can better co-manage these patients for improved outcomes. More local research is needed to understand the true prevalence of a co-diagnosis of HIV and cancer and in particular non-AIDS defining malignancies.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-hiv-malignancies-symposium/
LOCATION:Movenpick Hotel\, Nairobi
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190328T000000
DTEND;TZID=Africa/Nairobi:20190328T235959
DTSTAMP:20260425T013611
CREATED:20210421T195426Z
LAST-MODIFIED:20250622T142510Z
UID:4784-1553731200-1553817599@kesho-kenya.org
SUMMARY:Topic: Acute Leukaemia
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nProf. Nicholas Abinya Medical Oncologist and Dr. Anne Mwirigi Haematologist gave stimulating perspectives on their care of patients with AML in a public versus a private setting. This led to discussions on collaborations on improving standards of care in our country and in particular with regards to supportive care and financing. KESHO is now engaging with NHIF and the NCCP to outline a treatment package for these patients that factor other costs apart from direct chemotherapy drugs. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-acute-leukaemia/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190228T000000
DTEND;TZID=Africa/Nairobi:20190228T235959
DTSTAMP:20260425T013611
CREATED:20210421T200249Z
LAST-MODIFIED:20250622T142510Z
UID:4786-1551312000-1551398399@kesho-kenya.org
SUMMARY:Topic: Updates on Recently Launched Cancer Screening Guidelines
DESCRIPTION:[vc_row][vc_column][vc_column_text]In line with the launch of the Kenya Cancer Screening guidelines\, Dr Andrew Odhiambo Medical Oncologist and Dr Primus Ochieng Clinical Oncologist presented on their perspectives on the new guidelines and their experience in other settings outside of Kenya. The Screening Guidelines is as shown below: \n\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-updates-on-recently-launched-cancer-screening-guidelines/
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190131T000000
DTEND;TZID=Africa/Nairobi:20190131T235959
DTSTAMP:20260425T013611
CREATED:20210421T200621Z
LAST-MODIFIED:20250622T142510Z
UID:4791-1548892800-1548979199@kesho-kenya.org
SUMMARY:Topic: Updates in Breast Cancer Management
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nWe started off the year discussing the most common cancer in women in Kenya and worldwide with two presentations. Dr Miriam Mutebi Surgical Oncologist gave an update on the surgical techniques of breast cancer management and Dr Njoki Njiriani Clinical Oncologist talking on new therapies for advanced hormone positive breast cancer \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-updates-in-breast-cancer-management/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20181115T000000
DTEND;TZID=Africa/Nairobi:20181117T235959
DTSTAMP:20260425T013611
CREATED:20210417T030439Z
LAST-MODIFIED:20220303T081251Z
UID:4661-1542240000-1542499199@kesho-kenya.org
SUMMARY:The 5th Kenya International Cancer Conference
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Theme: Integrating Research and Practice                \n        \n    \n    [vc_tta_accordion][vc_tta_section title=”Executive Summary” tab_id=”1618600243140-acca4fba-be671a3a-4f3f”][vc_column_text]The latest cancer statistics show that the cancer burden is expected to rise to 18.1million new cases and 9.6million cancer deaths in 2018 globally. Kenya has less than 30 cancer specialists mostly in the urban settings against an increasing cancer population currently documented at 43\,000 patients across the country illuminating a dire professional deficit and much needed concerted effort by all players to curb the catastrophic effects of cancer burden. \nCancer control research therefore seeks to identify and evaluate means of reducing cancer morbidity and mortality and thereby improving the quality of life of people living with\, recovering from or dying of cancer. Knowledge of the facts and statistics\, plausible risk factors of disease and emergent complexes\, suitable interventions in response as well as the policies and frameworks that help facilitate cancer control is essential in reducing incidents\, rates and mortality due to cancer. Through research\, cancer experts are able to tackle cancer with community and country/region specific interventions. \nThe 5th International Cancer Conference in 2018 by KESHO hosted in partnership with the Ministry of Health\, Kenya\, brought together an average of more than 250 participants each conference day. They comprised both delegates and partners whose profile ranged from oncologists\, radiologists\, pharmacists\, medical officers and a myriad of players in cancer management and treatment including health authorities and experts from the state\, non-governmental organizations and projects working in screening and surveillance of risk and crisis management as well as scientists\, advocacy groups and individuals/persons living with cancer to discuss integrating cancer treatment practice and research. More than30% of the participants\, were doctors with the rest being diverse practitioners mitigating cancer related complexes. It was an opportunity to review and evaluate performance and discuss various advances made so far in cancer treatment and management both locally and globally and how to embrace them as well as create a platform to decentralize cancer information from few experts to devolved layers in cancer management such as general physicians and caregivers at county level. The program included diverse content from renowned experts in several related fields and a well versed keynote speaker from around the world and local clinical specialists and practitioners in research\, policy makers and cancer advocates to infuse a more holistic perspective. \nThe conference format included plenary sessions\, context specific breakout sessions\, illustrative exhibitions by sector players\, workshops including research workshop facilitated by international and local researchers who steer participants in navigating the enormous dilemma in conducting research (quantitative and qualitative)\, grant writing and getting published and the first ever KESHO-ASCO Joint Symposium showcasing KESHO members and ASCO faculty tackling cases in the setting of precision medicine and immunotherapy. Additionally\, there were social activities linked and tilted to the conference activities and themes such as a Gala Dinner by Texas Cancer Centre in Kenya enriched by a fashion show with cancer survivor runway models and a Cancer awareness concert by renowned celebrity artists. \nThe theme of the conference in 2018 was ‘Integrating Research and Practice’ with the main objective being to highlight the research work centred on cancer treatment and management and create a platform for local\, regional and international health care providers to present their work\, hear from each other\, learn and encourage collaboration.[/vc_column_text][/vc_tta_section][vc_tta_section title=”Sponsors” tab_id=”1618600243182-22e4f313-bf2f1a3a-4f3f”][vc_images_carousel images=”4559\,4560\,4561\,4664\,4648\,4645\,4698″ img_size=”full” onclick=”link_no” slides_per_view=”5″ wrap=”yes”][/vc_tta_section][vc_tta_section title=”Exhibitors” tab_id=”1618600981491-a82fabd7-47e61a3a-4f3f”][vc_column_text]The following were the exhibitors who participated in this conference:[/vc_column_text][vc_row_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nLancet\nBayer\nMetropolis\nSalama Pharmaceuticals\nSANOFI\nSUN Pharma\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nMERCK\nORIGENS Limited\nF&S Scientific\nCipla\nEldoret oncology\nMercury Healthcare solutions\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nApollo Hospitals\nLABIOFAM\nMSN\nHETERO Mylan\nIntas Pharmaceuticals Ltd\n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Attendance” tab_id=”1618602681315-0331dd50-f46e1a3a-4f3f”][vc_row_inner][vc_column_inner][vc_column_text]The 5th International Cancer Conference in 2018 by KESHO hosted in partnership with the Ministry of Health\, Kenya\, brought together more than 200 participants that comprised both delegates and partners and a myriad of players in cancer management and treatment including health authorities and experts from the state\, non-governmental organizations and projects working in screening and surveillance of risk and crisis management as well as scientists\, advocacy groups and individuals/persons living with cancer to discuss integrating cancer treatment practice and research. This year over 90 of the participants were doctors with the rest being diverse practitioners mitigating cancer related complexes. The program included diverse content from renowned experts in several related fields\, key note speakers from around the world and local clinical specialists and practitioners in research\, policy makers and cancer advocates to infuse a more holistic perspective. The attendance for the 5th International Cancer Conference in 2018 by KESHO was as follows:[/vc_column_text][vc_round_chart type=”doughnut” style=”custom” stroke_width=”2″ values=”%5B%7B%22title%22%3A%22Nurses%20and%20Support%20Staff%22%2C%22value%22%3A%2233%22%2C%22color%22%3A%22orange%22%2C%22custom_color%22%3A%22%238224e3%22%7D%2C%7B%22title%22%3A%22Local%20Doctors%20and%20Physicians%22%2C%22value%22%3A%2239%22%2C%22color%22%3A%22purple%22%2C%22custom_color%22%3A%22%23dd9933%22%7D%2C%7B%22title%22%3A%22Students%22%2C%22value%22%3A%229%22%2C%22color%22%3A%22pink%22%2C%22custom_color%22%3A%22%2381d742%22%7D%2C%7B%22title%22%3A%22Regional%20and%20International%20Delegates%22%2C%22value%22%3A%2219%22%2C%22color%22%3A%22green%22%2C%22custom_color%22%3A%22%23dd3333%22%7D%5D” css_animation=”bounceInDown”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Program” tab_id=”1618603042055-86340cec-10511a3a-4f3f”][vc_column_text]The programme for the 5th Kenya International Cancer Conference 2018. \n\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_tta_section][vc_tta_section title=”Resources” tab_id=”1618603068054-1a862002-c1861a3a-4f3f”][vc_row_inner][vc_column_inner][vc_column_text]The programme for the 5th Kenya International Cancer Conference 2018.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Photos” tab_id=”1618603088222-d75bc43c-cc851a3a-4f3f”][vc_row_inner][vc_column_inner][vc_column_text]View photos of the 2018 conference here[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][/vc_tta_accordion][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/the-5th-kenya-international-cancer-conference/
LOCATION:Crowne Plaza\, Nairobi\, Kenya.\, Kenya
CATEGORIES:Conferences
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20161124T000000
DTEND;TZID=Africa/Nairobi:20161126T235959
DTSTAMP:20260425T013611
CREATED:20210417T015953Z
LAST-MODIFIED:20220303T081150Z
UID:4640-1479945600-1480204799@kesho-kenya.org
SUMMARY:The 4th Kenya International Cancer Conference
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Theme: Taking Cancer Care to the Community                \n        \n    \n    [vc_tta_accordion][vc_tta_section title=”Executive Summary” tab_id=”1618600243140-acca4fba-be67ab7b-49cb”][vc_column_text]In partnership with Maseno university\, KESHO hosted its 4th International Cancer Conference this time in Kisumu\, Kenya. The 2016 Conference brought together oncologists and other healthcare professionals involved in or with an interest in cancer\, cancer advocacy groups\, healthcare policy and financing agencies to present on the following topics: \nCancer prevention\, screening\, early detection\n\nThe fight against cancer – Screening\, prevention and treatment.\nEnvironmental protection in cancer prevention.\nDiet\, lifestyle and cancer\n\nCancer Epidemiology and Diagnostics\n\nBurkitt’s lymphoma and the Eastern African ecosystem.\nCancer epidemiology in East Africa – the Lake Victoria plateau and the Indian Ocean coastal lowlands.\nManagement of HIV/AIDS-related cancers\nRole of PET/CT in cancer management.\nHow can we leap frog technology for cancer diagnosis in sub-Saharan Africa?\n\nPalliative Care\n\nEstablishment of palliative care centres in Eastern Africa – Challenges and Successes.\nHow to strengthen multidisciplinary cancer care in sub-Saharan Africa.\nEstablishing networks for cancer care and research in sub-Saharan Africa\nThe role of spirituality in cancer care: The pros and cons.\nCommunicating/breaking bad news/telling the diagnosis.\n\nCancer Control Planning\n\nEstablishment of comprehensive cancer care including high dose chemotherapy in sub-Saharan Africa – the hurdles and prospects.\nChallenges in increasing radiotherapy facilities in sub-Saharan Africa.\nEstablishment of County cancer care.\nCapacity building for cancer care in Eastern Africa.\nWhere is sub-Saharan Africa in in the era of personalized cancer therapy?\nAccess to cancer care in sub-Saharan Africa: The challenges and bottlenecks; the prospects.\nRole of Ministries of Health in Africa in Cancer Care.\nChallenges of alternative Cancer care; to integrate or not to integrate with conventional care?\nExponential Growth of the Medical Tourism Industry: Curse or Blessing?\n\nThe conference saw in attendance over 200 participants from 8 different countries around the world.[/vc_column_text][/vc_tta_section][vc_tta_section title=”Sponsors” tab_id=”1618600243182-22e4f313-bf2fab7b-49cb”][vc_images_carousel images=”4558\,4559\,4560\,4561\,4645\,4646\,4648″ img_size=”full” onclick=”link_no” slides_per_view=”6″ wrap=”yes”][/vc_tta_section][vc_tta_section title=”Exhibitors” tab_id=”1618600981491-a82fabd7-47e6ab7b-49cb”][vc_column_text]Twenty four exhibitors participated in this conference.[/vc_column_text][vc_row_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nTakeda\nCancer Alliance\nTCC\nBBMRI-ERIC\nAmpath Oncology\nGE\nLancet\nNairobi Hospital\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nAcino Switzerland\nUwezo\nBelaire\nAlexandria\nEli Lilly\nHenzo\nMedserv\nNovartis\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nSalama Pharmacy\nMax Foundation\nGenerics Africa\nJanssen Kenya\nSunpar Pharma\nApollo Hospital\nBecton Dickinson\nKNH\n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Attendance” tab_id=”1618602681315-0331dd50-f46eab7b-49cb”][vc_row_inner][vc_column_inner][vc_column_text]A total of 187 registered for the conference\, 158 attended. Twelve (12) international delegates attended the conference. See % attendance in the below chart.[/vc_column_text][vc_round_chart type=”doughnut” style=”custom” stroke_width=”2″ values=”%5B%7B%22title%22%3A%22Nurses%20and%20Support%20Staff%22%2C%22value%22%3A%2231%22%2C%22color%22%3A%22orange%22%2C%22custom_color%22%3A%22%239900cc%22%7D%2C%7B%22title%22%3A%22Local%20Doctors%20and%20Physicians%22%2C%22value%22%3A%2249%22%2C%22color%22%3A%22purple%22%2C%22custom_color%22%3A%22%23ff9900%22%7D%2C%7B%22title%22%3A%22Students%22%2C%22value%22%3A%226%22%2C%22color%22%3A%22pink%22%2C%22custom_color%22%3A%22%23009933%22%7D%2C%7B%22title%22%3A%22Regional%20and%20International%20Delegates%22%2C%22value%22%3A%2214%22%2C%22color%22%3A%22green%22%2C%22custom_color%22%3A%22%23993333%22%7D%5D” css_animation=”bounceInDown”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Program” tab_id=”1618603042055-86340cec-1051ab7b-49cb”][vc_column_text]Find below the programme for the 4th Kenya International Cancer Conference 2016. \n\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_tta_section][vc_tta_section title=”Resources” tab_id=”1618603068054-1a862002-c186ab7b-49cb”][vc_row_inner][vc_column_inner][vc_column_text]Find below the report for the 4th Kenya International Cancer Conference 2016.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Photos” tab_id=”1618603088222-d75bc43c-cc85ab7b-49cb”][vc_row_inner][vc_column_inner][vc_column_text]View 2014 conference photos[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][/vc_tta_accordion][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/the-4th-kenya-international-cancer-conference/
LOCATION:Acacia Premier\, Kisumu\, Kenya.\, Kenya
CATEGORIES:Conferences
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20141127T000000
DTEND;TZID=Africa/Nairobi:20141129T235959
DTSTAMP:20260425T013611
CREATED:20160819T214743Z
LAST-MODIFIED:20220107T101429Z
UID:2233-1417046400-1417305599@kesho-kenya.org
SUMMARY:The 3rd Kenya International Cancer Conference
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Theme: Let Us Talk About Cancer.                \n        \n    \n    [vc_tta_accordion][vc_tta_section title=”Executive Summary” tab_id=”1618600243140-acca4fba-be67″][vc_column_text]The Kenya Society of Haematology and Oncology (KESHO) organized its third annual conference from 27 to 30 November 2014 in Nairobi with the theme: Let us talk about cancer. The conference brought together specialists who contribute to the treatment and management of cancer cases. These included haematologists\, nurses\, oncologists\, pathologists\, psychological counsellors\, radiotherapists and surgeons. The importance of a multidisciplinary approach to cancer management and treatment was emphasized. \nIn addition\, the need to reduce the cost of treatment and address the mass exodus of patients seeking treatment abroad was also raised. Capacity building was also highlighted; this would be done in tandem with acquisition of more diagnostic and treatment facilities in public hospitals in the country. Government was urged to provide incentives for private sector players to invest in the devolved government framework especially in this field. The role of cancer registries was highlighted in helping map the incidences of various cancers in the country. Sickle cell disease and the establishment of a registry was also discussed. \nCancer is among the non-communicable diseases (NCDs) that are increasingly becoming prevalent in Kenya. This could be attributed to changing lifestyles and other factors. The cost of treating the disease is beyond reach for many patients and their families. Cost influences clinical decisions on investigations and treatment issues\, posing a challenge to clinicians even when the expertise and equipment to provide the best quality care is available in the country\, mainly in private institutions. It was clear that both government and private sector have a role to play in addressing the challenges in cancer management; this can be done through public-private partnerships. The experience of setting up a cancer centre as shared by Texas Cancer Center would guide other players in the establishment of similar facilities. \nIt was clear that cancer management cannot only be handled by clinicians\, the patients\, relatives and concerned members of the public have a role to play in creating awareness especially on screening and early detection. Advocacy at both local and international levels is also necessary to ensure that resources are made available for addressing the disease. \nChallenges faced by clinicians in handling cancers of the breast\, colon and prostate together with sickle cell disease were discussed in detail. The interactive discussion sessions provided participants an opportunity to address issues raised in presentations.[/vc_column_text][/vc_tta_section][vc_tta_section title=”Sponsors” tab_id=”1618600243182-22e4f313-bf2f”][vc_images_carousel images=”4558\,4559\,4560\,4561″ img_size=”full” onclick=”link_no” slides_per_view=”5″ wrap=”yes”][/vc_tta_section][vc_tta_section title=”Exhibitors” tab_id=”1618600981491-a82fabd7-47e6″][vc_column_text]The 3rd Kenya International Cancer Conference attracted 13 exhibitors including sponsors:[/vc_column_text][vc_row_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nAstra Zeneca\nTexas Cancer Centre\nNovartis\nRoche\nPema Scientifics\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nGalaxy\nCrown\nLancet\nAcino Switzerland\nHenzo\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nMacNaughton\nMSD\nKenyatta National Hospital\n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Attendance” tab_id=”1618602681315-0331dd50-f46e”][vc_row_inner][vc_column_inner][vc_column_text]The conference brought together 187 specialists who contribute to the treatment and management of cancer cases. These included haematologists\, nurses\, oncologists\, pathologists\, psychological counsellors\, radiotherapists and surgeons. Challenges faced by clinicians in handling cancers of the breast\, colon and prostate together with sickle cell disease were discussed in detail. We attracted over 67 doctors from Kenya and the region and 11 delegates from outside Africa. The % attendance for the 3rd Kenya International Cancer Conference was as follows:[/vc_column_text][vc_round_chart type=”doughnut” style=”custom” stroke_width=”2″ values=”%5B%7B%22title%22%3A%22Nurses%20and%20Support%20Staff%22%2C%22value%22%3A%2249%25%22%2C%22color%22%3A%22orange%22%2C%22custom_color%22%3A%22%23ba9b2a%22%7D%2C%7B%22title%22%3A%22Local%20Doctors%20and%20Physicians%22%2C%22value%22%3A%2234%22%2C%22color%22%3A%22purple%22%2C%22custom_color%22%3A%22%232860af%22%7D%2C%7B%22title%22%3A%22Students%22%2C%22value%22%3A%2211%22%2C%22color%22%3A%22pink%22%2C%22custom_color%22%3A%22%23ff9900%22%7D%2C%7B%22title%22%3A%22Regional%20and%20International%20Delegates%22%2C%22value%22%3A%226%22%2C%22color%22%3A%22green%22%2C%22custom_color%22%3A%22%2300c1cf%22%7D%5D” css_animation=”bounceInDown”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Program” tab_id=”1618603042055-86340cec-1051″][vc_column_text]Find below the programme for the 3rd Kenya International Cancer Conference. \n\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_tta_section][vc_tta_section title=”Resources” tab_id=”1618603068054-1a862002-c186″][vc_row_inner][vc_column_inner][vc_column_text] \nFind below the report for the 3rd Kenya International Cancer Conference 2014. \n[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n        PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Photos” tab_id=”1618603088222-d75bc43c-cc85″][vc_row_inner][vc_column_inner][vc_column_text]View 2014 conference photos[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][/vc_tta_accordion][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/the-3rd-kenya-international-cancer-conference-2/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:Conferences
END:VEVENT
END:VCALENDAR